Results 11 to 20 of about 306,084 (179)

Interferon alfa-associated retinopathy

Journal of Osteopathic Medicine, 1997
Abstract Interferon alia and its related compounds have been used for more than 10 years in the treatment of a number of conditions including viral illnesses, childhood hemangiomas, various cancers, and leukemia. The potential applications for this class of medication continue to grow. The use of interferon alia in experimental protocols
R B, Chambers, A, Downie, B, Foote, F H, Davidorf   +3 more
openaire   +3 more sources

Thyrotoxicosis With Pegylated Interferon Alfa-2b [PDF]

Archives of Dermatology, 2010
Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with micrometastatic disease.
Lowndes, SA, Asher, R, Middleton, MR
openaire   +3 more sources

Tratamento clínico do linfangioma com alfa-2a-interferon Treatment of lymphangioma with interferon-alpha-2a

Jornal de Pediatria, 2001
OBJETIVO: descrever os resultados obtidos com o uso do alfa-2a-interferon no tratamento de pacientes pediátricos com linfangiomas irressecáveis ou refratários a outros tratamentos.
Reynaldo J.S.P. de Souza, Luiz G. Tone
doaj   +2 more sources

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C:a retrospective study using the Japanese Interferon Database

Drug Design, Development and Therapy, 2014
Izumi Sato,1 Takuro Shimbo,2 Yohei Kawasaki,3 Naohiko Masaki41Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan; 2Ohta Nishinouchi Hospital, Fukushima, Japan ...
Sato I, Shimbo T, Kawasaki Y, Masaki N
doaj   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Leifeld, Ludger, Spengler, Ulrich, Hoffmann, Robert M., Berg, Thomas, Hopf, Uwe, Pape, Gerd R., Teuber, Gerlinde, Lafrenz, Michael, Zeuzem, Stefan, Gerd R. Pape, Stefan Zeuzem, Ludger Leifeld, Ulrich Spengler, Robert M. Hoffmann, Michael Lafrenz, Uwe Hopf, Gerlinde Teuber, Thomas Berg   +17 more
core   +1 more source

Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism [PDF]

, 2003
Background. Tumor necrosis factor-alpha (TNF-alpha) is involved in the pathogenesis of chronic active hepatitis C. Polymorphisms in the promoter region of the TNF-alpha gene can alter the TNF-alpha expression and modify the host immune response.
Konig, A., Folwaczny, Christian, Schmidt, F., Simperl, C., Schaefer, M., Torok, P., Glas, J., Schiemann, Uwe, Martin, K.   +8 more
core   +1 more source

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. [PDF]

, 2009
OBJECTIVES: This study assesses whether pegylated interferon and ribavirin is cost-effective compared with no antiviral treatment provided in routine clinical practice, for different patient subgroups.
Grishchenko, Marina, Sweeting, Michael J, Thomson, Brian J, Irving, William L, Ryder, Stephen D, Grieve, Richard D, Trent HCV Study Group, De Angelis, Daniela   +7 more
core   +1 more source

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection [PDF]

, 2013
Background & Aims: Genetic variations near the interferon lambda 3 gene (IFNL3, IL28B) are the most powerful predictors for sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, compared to other biochemical or ...
Simone Susser (48294), Annika Brodzinski, Thomas Berg (186372), Migaud, Pascal, Jacob George (205614), Brodzinski, Annika, Tobias Müller, Susser, Simone, Stephan Böhm (334611), Sarrazin, Christoph, Christoph Sarrazin (48298), Pascal Migaud, Schott, Eckart, Bömmel, Florian van, Heiko Witt, Florian van Bömmel, Janett Fischer, Christoph Sarrazin, Stewart, Graeme, Graeme Stewart, Witt, Heiko, Thomas Berg, Simone Susser, Balazs Fülöp, Fülöp, Balazs, Stephan Böhm, Annika Brodzinski (477753), Balazs Fülöp (477754), Müller, Tobias, Fischer, Janett, Böhm, Stephan, Berg, Thomas, Tobias Müller (163591), Janett Fischer (477751), Eckart Schott (320945), Graeme Stewart (208243), Jacob George, Heiko Witt (161481), Pascal Migaud (477752), George, Jacob, Eckart Schott, Florian van Bömmel (477755)   +41 more
core   +1 more source

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C [PDF]

, 2012
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Jörg Bojunga, Raffaele Malinverni, Gerlach, Tilman J., Gerlach, Tilman J, Tilman J Gerlach, Swiss Hepatitis C Cohort Study Group,, Berg, T., Kutalik, Z., Stephanie Bibert, Christian M Lange, Geier, Andreas, Dufour, Jean-François Jacques, Thomas Berg, Malinverni, Raffaele, Regenass, S., Burgisser, Philippe, Regenass, Stephan, Badenhoop, Klaus, Bojunga, Jörg, Lange, Christian M, Dufour, J. F., Stephan Regenass, Gerlach, Tilman Joern, Swiss Hepatitis C Cohort Study Group, Bochud, P. Y., Dufour, Jean-Francois, Bojunga, J., Andreas Geier, Stefan Zeuzem, Negro, F., Cerny, A., Zoltan Kutalik, Lange, Christian, Pierre-Yves Bochud, Sarrazin, C., Tobias Müller, Sarrazin, Christoph, Lange, C. M., Cerny, Andreas, Kutalik, Zoltán, Bibert, S., Malinverni, R., Moradpour, Darius, Christoph Sarrazin, Burgisser, P., Gerlach, T. J., Moradpour, D., Bibert, Stephanie, Klaus Badenhoop, Zeuzem, S., Negro, Francesco, Müller, Tobias, Badenhoop, K., Andreas Cerny, Bochud, Pierre-Yves, Geier, A., Heim, M. H., Muller, T., Francesco Negro, Berg, Thomas, Markus H Heim, Heim, Markus H., Darius Moradpour, Jean-Francois Dufour, Philippe Burgisser, Heim, Markus H, Zeuzem, Stefan   +66 more
core   +2 more sources